Jump to: navigation, search
Ampeframone Wiki Str.png
Clinical data
Trade namesTenuate
  • US: B (No risk in non-human studies)
Routes of
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life4-6 hours (metabolites)[1]
ExcretionUrine (>75%)[1]
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass205.30 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Amfepramone


Most recent articles on Amfepramone

Most cited articles on Amfepramone

Review articles on Amfepramone

Articles on Amfepramone in N Eng J Med, Lancet, BMJ


Powerpoint slides on Amfepramone

Images of Amfepramone

Photos of Amfepramone

Podcasts & MP3s on Amfepramone

Videos on Amfepramone

Evidence Based Medicine

Cochrane Collaboration on Amfepramone

Bandolier on Amfepramone

TRIP on Amfepramone

Clinical Trials

Ongoing Trials on Amfepramone at Clinical

Trial results on Amfepramone

Clinical Trials on Amfepramone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Amfepramone

NICE Guidance on Amfepramone


FDA on Amfepramone

CDC on Amfepramone


Books on Amfepramone


Amfepramone in the news

Be alerted to news on Amfepramone

News trends on Amfepramone


Blogs on Amfepramone


Definitions of Amfepramone

Patient Resources / Community

Patient resources on Amfepramone

Discussion groups on Amfepramone

Patient Handouts on Amfepramone

Directions to Hospitals Treating Amfepramone

Risk calculators and risk factors for Amfepramone

Healthcare Provider Resources

Symptoms of Amfepramone

Causes & Risk Factors for Amfepramone

Diagnostic studies for Amfepramone

Treatment of Amfepramone

Continuing Medical Education (CME)

CME Programs on Amfepramone


Amfepramone en Espanol

Amfepramone en Francais


Amfepramone in the Marketplace

Patents on Amfepramone

Experimental / Informatics

List of terms related to Amfepramone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Amfepramone (INN)[note 1] is a stimulant drug of the phenethylamine, amphetamine, and cathinone classes that is used as an appetite suppressant.[2][3] It is used in the short-term management of obesity, along with dietary and lifestyle changes.[2] Amfepramone is most closely chemically related to the antidepressant and smoking cessation aid bupropion (previously called amfebutamone), which has also been developed as a weight-loss medicine when in a combination product with naltrexone.[4]


Amfepramone itself lacks any affinity for the monoamine transporters and instead functions as a prodrug to ethcathinone.[5] Ethcathinone (and therefore amfepramone as well) is a very weak dopaminergic and serotonergic, and is approximately 10x and 20x stronger on norepinephrine in comparison, respectively.[5] As a result, ethcathinone and amfepramone can essentially be considered a member of the class of drugs known as norepinephrine releasing agents (NRAs).


Amfepramone is believed to have relatively low abuse potential.[6][7][8][9] but recently there have been reports of teens and adults in the UK abusing this drug, known as "tombstones" to the abusers.


Amfepramone is classified as a Schedule IV controlled substance in the United States. It is also a Schedule IV controlled substance in Canada. In the UK Amfepramone is a class C drug [10] and as a medicine, it is a Schedule 3 Controlled Drug which requires safe custody. It's not US FDA approved.


  1. Propiophenone is brominated to produce α-bromopropiophenone.
  2. This is reacted with diethylamine to yield the product, diethylpropion.[11][12]

See also


  1. Another medically-utilized name is diethylpropion (BAN and AAN). Chemical names include: α-methyl-β-keto-N,N-diethylphenethylamine, N,N-diethyl-β-ketoamphetamine and N,N-diethylcathinone. Brand names include: Anorex, Linea, Nobesine, Prefamone, Regenon, Tepanil and Tenuate.


  1. 1.0 1.1 "SPC-DOC_PL 16133-0001" (PDF). Medicines Healthcare products Regulatory Agency. Essential Nutrition Ltd. 18 November 2011. Retrieved 18 July 2014.
  2. 2.0 2.1 Brayfield, A, ed. (30 January 2013). "Diethylpropion Hydrochloride". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 18 July 2014.
  3. Template:Cite document
  4. Arias, HR; Santamaría, A; Ali, SF (2009). "Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion". International Review of Neurobiology. 88: 223–55. doi:10.1016/S0074-7742(09)88009-4. PMID 19897080.
  5. 5.0 5.1 Rothman, RB; Baumann, MH (2006). "Therapeutic Potential of Monoamine Transporter Substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
  6. Cohen, S (1977). "Diethylpropion (Tenuate): An Infrequently Abused Anorectic". Psychosomatics. 18 (1): 28–33. doi:10.1016/S0033-3182(77)71101-6. PMID 850721.
  7. Jasinski, DR; Krishnan, S (June 2009). "Abuse Liability and Safety of Oral Lisdexamfetamine Dimesylate in Individuals with a History of Stimulant Abuse". Journal of Psychopharmacology. 23 (4): 419–427. doi:10.1177/0269881109103113. PMID 19329547.
  8. "Tepanil (diethylpropion hydrochloride) tablet, extended release". Dailymed. National Institutes of Health.
  9. Caplan, J (May 1963). "Habituation to Diethylpropion (Tenuate)". Canadian Medical Association Journal. 88: 943–944. PMC 1921278. PMID 14018413.
  10. "Class C Drugs". Schedule 2 Controlled Drugs. UK Legislation.
  11. US patent 3001910, "Anorexigenic Propiophenones", issued 1961-09-26, assigned to Temmler-Werke 
  12. Template:Cite doi

Template:Anorectics Template:Catecholaminergics